Absci Strengthens Leadership with New Board Member
Absci, a pioneering clinical-stage biopharmaceutical company focused on advancing breakthrough therapeutics through generative AI, has announced an important addition to its Board of Directors. Veteran industry leader Mary Szela joins the team, bringing with her a wealth of experience and strategic vision.
Mary Szela's Impressive Background
Mary Szela has a distinguished career in the biopharmaceutical sector, having held key roles that shaped the development and commercialization of significant therapies. Notably, during her time at Abbott Laboratories, she was instrumental in the global launch of Humira, contributing to its expansion into multiple therapeutic areas.
A Vision for the Future
Sean McClain, Founder and CEO of Absci, expressed enthusiasm regarding Szela's appointment, stating, "Mary has been a driving force in bringing successful therapies to market. Her extensive experience will be invaluable as we work on potentially transformative programs like ABS-201 for androgenetic alopecia, and continue to expand our pipeline of innovative AI-designed biologics."
Expertise on the Board
In addition to her role at Absci, Mary Szela currently serves as the Chief Executive Officer and Director of TriSalus Life Sciences, and has board experience with companies such as Prometheus Biosciences, Kura Oncology, and Novo Nordisk. Her strong educational background includes a B.S. in Nursing and an MBA from the University of Illinois at Chicago.
Szela on Absci's Transformation
Reflecting on Absci's journey, Szela remarked, "I have witnessed Absci transition from a data-first platform to a leading force in AI-driven drug discovery. It's exciting to see a growing pipeline of high-potential biologics designed with cutting-edge technology. I'm honored to join at such a critical juncture and eager to contribute to our mission of delivering superior biologics to patients more rapidly."
Development Pipeline Expansion
Under Szela’s influence, Absci aims to continue advancing its AI-designed therapeutic pipeline. This includes the promising ABS-101, targeted at treating inflammatory bowel disease (IBD), with interim data from Phase 1 trials expected soon, and ABS-201, an innovative approach for androgenetic alopecia that is set to enter clinical trials in the near future.
About Absci
Absci is leading the way in the future of drug discovery through generative design. The company's Integrated Drug Creation™ platform combines advanced AI technologies with a robust synthetic biology data engine, allowing for the rapid innovation of therapeutics that tackle challenging medical conditions. Through their unique approach, Absci ensures each development phase is reinforced by robust data and validation in wet labs, resulting in precise and effective therapeutic designs.
With its headquarters in Vancouver, WA, Absci also operates an AI Research Lab in New York City and an Innovation Center in Switzerland. The company collaborates with prominent pharmaceutical and biotech partners, enhancing its pipeline, which includes the development of ABS-101, aimed at IBD, and ABS-201, a potential breakthrough for androgenetic alopecia.
Investor Contact Information
For inquiries, please contact:
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact Information
For media inquiries, reach out to:
press@absci.com
Frequently Asked Questions
Who is Mary Szela?
Mary Szela is a seasoned biopharma executive with experience in leading the commercialization of notable treatments like Humira.
What is Absci's specialty?
Absci specializes in advancing drug discovery through generative AI, focusing on creating innovative biologics.
What are the programs mentioned in the article?
The article discusses programs like ABS-201 for androgenetic alopecia and ABS-101 for inflammatory bowel disease.
Where is Absci headquartered?
Absci’s headquarters are located in Vancouver, WA, with additional facilities in New York City and Switzerland.
How can investors contact Absci?
Investors can contact Alex Khan, VP of Finance & Investor Relations, via email at investors@absci.com.
